Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRA

  • PDF / 1,220,262 Bytes
  • 11 Pages / 595.276 x 790.866 pts Page_size
  • 24 Downloads / 217 Views

DOWNLOAD

REPORT


ORIGINAL ARTICLE – CLINICAL ONCOLOGY

Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS‑wild‑type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109) A. Kurreck1 · M. Geissler2 · U. M. Martens3 · J. Riera‑Knorrenschild4 · J. Greeve5 · A. Florschütz6 · S. Wessendorf2 · T. Ettrich7 · S. Kanzler8 · D. Nörenberg9 · M. Seidensticker10 · S. Held11 · P. Buechner‑Steudel12 · J. Atzpodien13 · V. Heinemann14,15 · S. Stintzing1 · T. Seufferlein7 · A. Tannapfel16 · A. C. Reinacher‑Schick17 · D. P. Modest1  Received: 15 April 2020 / Accepted: 12 May 2020 © The Author(s) 2020

Abstract Purpose  In mCRC, disease dynamics may play a critical role in the understanding of long-term outcome. We evaluated depth of response (DpR), time to DpR, and post-DpR survival as relevant endpoints. Methods  We analyzed DpR by central review of computer tomography images (change from baseline to smallest tumor diameter), early tumor shrinkage (≥ 20% reduction in tumor diameter at first reassessment), time to DpR (study randomization to DpR-image), post-DpR progression-free survival (pPFS = DpR-image to tumor progression or death), and post-DpR overall survival (pOS = DpR-image to death) with special focus on BRAF status in 66 patients and primary tumor site in 86 patients treated within the VOLFI-trial, respectively. Results  BRAF wild-type (BRAF-WT) compared to BRAF mutant (BRAF-MT) patients had greater DpR (− 57.6% vs. − 40.8%, p = 0.013) with a comparable time to DpR [4.0 (95% CI 3.1–4.4) vs. 3.9 (95% CI 2.5–5.5) months; p = 0.8852]. pPFS was 6.5 (95% CI 4.9–8.0) versus 2.6 (95% CI 1.2–4.0) months in favor of BRAF-WT patients (HR 0.24 (95% CI 0.11–0.53); p